AstraZeneca, a pharmaceutical company, that developed one of the vaccines for COVID-19, will collaborate with Absci, a United States-based Artificial Intelligence biologics firm. This collaboration is expected to design an antibody for cancer, stated Cointelegraph.
With insights from the Financial Times report on December 3, 2023, AstraZeneca will invest about $247 million in research and development for Absci. The collaboration aims to create a zero-shot generative AI model, which would work on creating new antibody therapeutics for cancer and improving existing ones. It is believed that the report didn’t specify the type or types of cancer involved.
“AI is enabling us to not only increase the success and speed of our biologics discovery process, but also enhance the diversity of the biologics we discover,” Puja Sapra, VP, AstraZeneca senior, explained.
It is believed that AstraZeneca will help to leverage its AI work, according to a Reuters report. Absci is expected to have been contacted for more information but hasn’t replied yet, Cointelegraph concluded.
(With insights from Cointelegraph)
